A Single Dose Trial to Evaluate the Pharmacokinetics of Testosterone and Anastrozole

Mammographic Density Clinical Trial

Official title:

A Single Dose Trial to Evaluate the Pharmacokinetics of Testosterone and Anastrozole From Subcutaneous Testosterone and Anastrozole (T+Ai) in Premenopausal Women

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03314298
• Other study ID #: HAV-001
• Status: Completed
• Phase: Phase 1
• First received: August 6, 2017
• Last updated: April 17, 2018
• Start date: August 14, 2017
• Est. completion date: April 17, 2018

Study information

• Verified date: October 2017
• Source: Havah Therapeutics Pty Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A single dose trial to evaluate the pharmacokinetics of testosterone and anastrozole from subcutaneous testosterone and anastrozole (T+Ai) in premenopausal women

Description:

The trial is of open label single centre design. The serum concentrations of testosterone and plasma concentrations of anastrozole will be measured in 12 premenopausal women. Participants will be stratified in a 50:50 manner in two BMI (Body Mass Index) groups, <25 and 25 kg/m2, respectively. There will be a lead group of two participants in whom the serum/plasma concentrations will be examined after the first four weeks, to determine whether the sampling schedule adequately describes the serum/plasma concentration-time profiles or should be adjusted.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 11
• Est. completion date: April 17, 2018
• Est. primary completion date: April 17, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 35 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Agree to and be capable of understanding and signing an Informed Consent Form.

2. Patients seeking treatment with Investigational Product for the reduction in high mammographic breast density (MBD).

3. Pre-menopausal levels of Follicular stimulating hormone/Leutinizing hormone/estradiol(follicle stimulating hormone/luteinizing hormone/oestrogen) according to the definition of "pre-menopausal range" for the laboratory involved.

4. Volpara Density volumetric breast density of =15.5% (combined average both breasts)

5. Age between 35-55 years inclusive.

6. Body weight between 50-90 kg inclusive.

7. BMI between 20-30 kg/m2 inclusive.

8. Good venous access for venepuncture.

9. In good general health without clinically significant cardiac, respiratory, or psychiatric disease.

10. Negative pregnancy test in women of childbearing potential (premenopausal or less than 12 months of amenorrhea post-menopause, and who have not undergone surgical sterilisation), no more than seven days before the first dose of Investigational Product.

11. For women of childbearing potential who are sexually active, agreement to use a highly effective, non-hormonal form of contraception (Mirena (TM) allowed) during and for at least six months after completion of treatment with Investigational Product; OR, a fertile male partner willing and able to use effective non-hormonal means of contraception (barrier method of contraception in conjunction with spermicidal jelly, or surgical sterilisation) during and for at least six months after completed dosing Investigational Product.

Exclusion Criteria:

1. Presence of breast cancer.

2. Previous or concomitant other malignancy (non-breast, other than skin) within the previous five years.

3. Diabetes mellitus or glucose intolerance defined as a fasting glucose of = 6 mmol/L.

4. History of coronary artery disease.

5. Risk of transmitting Human Immunodeficiency Virus or viral hepatitis via infected blood.

6. Existing testosterone, oestrogen and/or anastrozole treatment.

7. Concomitant medication which induces or inhibits CYP3A4 (Listed in Appendix A).

8. Current warfarin usage.

9. Prolonged systemic corticosteroid treatment, inhalation and topical steroids allowed.

10. Known hypersensitivity to any component of Investigational Product.

11. Systemic reproductive hormone replacement therapy.

12. Systemic hormonal contraception.

13. Participation in another clinical trial of an Investigational Product within 30 days of entry into the present trial or within 4-5 half-lives of the Investigational Product, whichever is the longer.

14. Use of any product containing ginseng within 30 days of screening.

15. Pregnant or lactating women.

16. Unable to comply with trial requirements.

Related Conditions & MeSH terms

• Mammographic Density

Intervention

Drug:
• testosterone anastrozole
subcutaneous testosterone and anastrozole

Locations

Country	Name	City	State
Australia	Wellend Health	Toorak Gardens	South Australia

Sponsors (1)

Lead Sponsor	Collaborator
Havah Therapeutics Pty Ltd

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	testosterone Cmax	Peak Plasma Concentration	Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.
Primary	testosterone AUC	Area under the plasma concentration versus time curve	Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.
Primary	testosterone T1/2	plasma half-life	Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.
Primary	anastrozole Cmax	Peak Plasma Concentration	Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.
Primary	anastrozole AUC	Area under the plasma concentration versus time curve	Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.
Primary	anastrozole T1/2	plasma half-life	Day 1, blood samples will be taken pre-dose and at 1, 2, 4, 8 and 12 hours and 9 am in the morning on Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71 and 85.
Secondary	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	To assess the safety and tolerability of T+Ai following a single dose of T+Ai by subcutaneous implantation.; Biochemical and hematological will be evaluated and the number of participants with abnormal values or adverse events that are related to treatment will be recorded	The outcome measures will be reported weekly until study completion-3 months
Secondary	dihydrotestosterone metabolism	To description of the time course of dihydrotestosterone serum concentrations.	3 months
Secondary	breast elasticity	Breast tissue elasticity will be measured by shear wave ultrasound at baseline and on Days 29, 57 and 85. A Supersonic Ultrasound will be carried out by four quadrant analysis of each breast with 6x3mm Q box analyses measured in kPa.	Breast tissue elasticity will be measured by shear wave ultrasound at baseline and on Days 29, 57 and 85